Clinical characterization of long-term multiple sclerosis (COLuMbus) patients in Argentina: A cross-sectional non-interventional study

Mult Scler Relat Disord. 2024 Mar:83:105421. doi: 10.1016/j.msard.2023.105421. Epub 2023 Dec 31.

Abstract

Background: Most Multiple Sclerosis (MS) clinical trials fail to assess the long-term effects of disease-modifying therapies (DMT) or disability.

Methods: COLuMbus was a single-visit, cross-sectional study in Argentina in adult patients with ≥10 years of MS since first diagnosis. The primary endpoint was to determine patient disability using the Expanded Disability Status Scale (EDSS). The secondary endpoints were to evaluate the distribution of diagnoses between relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS), patient demographics, disease history, and the risk of disability progression. The relationship between baseline characteristics and the current disability state and the risk of disability progression was assessed.

Results: Out of the 210 patients included, 76.7 % had a diagnosis of RRMS and 23.3 % had been diagnosed with SPMS, with a mean disease duration of 17.9 years and 20.5 years, respectively. The mean delay in the initial MS diagnosis was 2.6 years for the RRMS subgroup and 2.8 years for the SPMS subgroups. At the time of cut-off (28May2020), 90.1 % (RRMS) and 75.5 % (SPMS) of patients were receiving a DMT, with a mean of 1.5 and 2.0 prior DMTs, respectively. The median EDSS scores were 2.5 (RRMS) and 6.5 (SPMS). In the RRMS and SPMS subgroups, 23 % and 95.9 % of patients were at high risk of disability, respectively; the time since first diagnosis showed a significant correlation with the degree of disability.

Conclusions: This is the first local real-world study in patients with long-term MS that highlights the importance of recognizing early disease progression to treat the disease on time and delay disability.

Keywords: Expanded disability status scale; MSProDiscuss™ tool; Multiple sclerosis; Relapsing-remitting; Secondary progressive.

MeSH terms

  • Adult
  • Argentina / epidemiology
  • Cross-Sectional Studies
  • Disease Progression
  • Humans
  • Multiple Sclerosis* / diagnosis
  • Multiple Sclerosis* / epidemiology
  • Multiple Sclerosis* / therapy
  • Multiple Sclerosis, Chronic Progressive* / diagnosis
  • Multiple Sclerosis, Chronic Progressive* / drug therapy
  • Multiple Sclerosis, Chronic Progressive* / epidemiology
  • Multiple Sclerosis, Relapsing-Remitting* / diagnosis
  • Multiple Sclerosis, Relapsing-Remitting* / epidemiology
  • Multiple Sclerosis, Relapsing-Remitting* / therapy